FR16C0031I1 - - Google Patents

Info

Publication number
FR16C0031I1
FR16C0031I1 FR16C0031C FR16C0031I1 FR 16C0031 I1 FR16C0031 I1 FR 16C0031I1 FR 16C0031 C FR16C0031 C FR 16C0031C FR 16C0031 I1 FR16C0031 I1 FR 16C0031I1
Authority
FR
France
Prior art keywords
hiv
mercaptoacetanilides
conr
triazolyl
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR16C0031I1 publication Critical patent/FR16C0031I1/fr
Application granted granted Critical
Publication of FR16C0031I2 publication Critical patent/FR16C0031I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
FR16C0031C 2004-08-25 2016-07-29 S-triazolyl alpha -mercaptoacetanilides en tant qu'inhibiteurs de la transcriptase inverse du vih Active FR16C0031I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60421904P 2004-08-25 2004-08-25
US60422004P 2004-08-25 2004-08-25
US68635105P 2005-05-31 2005-05-31
EP05790722A EP1789039B1 (en) 2004-08-25 2005-08-25 S-triazolyl alpha -mercaptoacetanildes as inhibitors of hiv reverse transcriptase

Publications (2)

Publication Number Publication Date
FR16C0031I1 true FR16C0031I1 (zh) 2016-09-23
FR16C0031I2 FR16C0031I2 (fr) 2017-03-31

Family

ID=36000576

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0031C Active FR16C0031I2 (fr) 2004-08-25 2016-07-29 S-triazolyl alpha -mercaptoacetanilides en tant qu'inhibiteurs de la transcriptase inverse du vih

Country Status (32)

Country Link
US (8) US7947721B2 (zh)
EP (5) EP2135608B8 (zh)
JP (2) JP4952943B2 (zh)
KR (1) KR101241716B1 (zh)
CN (2) CN101083987B (zh)
AT (2) ATE528001T1 (zh)
AU (2) AU2005280130C9 (zh)
BR (2) BRPI0520870B8 (zh)
CA (1) CA2578068C (zh)
CY (2) CY1112221T1 (zh)
DK (1) DK2135608T3 (zh)
EA (2) EA014737B1 (zh)
EC (1) ECSP077322A (zh)
ES (2) ES2374773T3 (zh)
FR (1) FR16C0031I2 (zh)
HK (1) HK1133582A1 (zh)
HR (1) HRP20130075T1 (zh)
HU (1) HUS1600034I1 (zh)
IL (3) IL181523A (zh)
IN (1) IN2014CN03762A (zh)
LT (1) LTC2135608I2 (zh)
LU (1) LU93169I2 (zh)
ME (1) ME01512B (zh)
MX (1) MX2007002236A (zh)
NL (1) NL300825I2 (zh)
NZ (2) NZ581376A (zh)
PL (1) PL2135608T3 (zh)
PT (1) PT2135608E (zh)
RS (1) RS52632B (zh)
SG (2) SG185992A1 (zh)
SI (1) SI2135608T1 (zh)
WO (1) WO2006026356A2 (zh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
EP2135608B8 (en) 2004-08-25 2012-03-21 Ardea Biosciences, Inc. S-triazolyl alpha -mercaptoacetanilides as inhibitors of HIV reverse transcriptase
KR101542629B1 (ko) 2007-05-30 2015-08-06 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역전사효소 억제제
WO2009030996A1 (en) * 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
SI2217577T1 (sl) 2007-11-27 2014-11-28 Ardea Biosciences, Inc. Nove spojine in sestavki ter metode uporabe
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
AU2009289647C1 (en) 2008-09-04 2013-03-21 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
EP2349258A1 (en) * 2008-10-24 2011-08-03 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( l-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triazol-3-ylthio) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
WO2010048592A1 (en) * 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
CA2760940A1 (en) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Methods of modulating uric acid levels
CN102040546B (zh) * 2009-10-10 2014-10-15 台州市华南医化有限公司 一种4-环丙基-1-异硫氰基萘的制备方法及中间体4-环丙基-1-萘甲醛肟/卤化物
SG182404A1 (en) * 2010-01-08 2012-08-30 Ardea Biosciences Inc Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
CA2794798C (en) 2010-03-30 2017-05-30 Ardea Biosciences, Inc. Treatment of gout
LT2582683T (lt) 2010-06-15 2018-06-11 Ardea Biosciences, Inc. Podagros ir hiperuricemijos gydymas
CA2802692C (en) 2010-06-16 2016-01-05 Ardea Biosciences, Inc. Phenylthioacetate compounds useful as uricosuric agents
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
CN101899013B (zh) * 2010-07-12 2012-07-25 山东大学 2-(2-取代芳基-2h-1,2,4-三唑-3-巯基)乙酰胺衍生物及其制备方法与应用
EP2627331A4 (en) * 2010-10-15 2014-03-12 Ardea Biosciences Inc METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES
MX2013007505A (es) 2010-12-30 2013-08-01 Ardea Biosciences Inc Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1 -il)-4h-1,2,4-triazol-3-iltio)acetico y usos de los mismos.
WO2013067425A1 (en) 2011-11-03 2013-05-10 Ardea Biosciences Inc. 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
AR091651A1 (es) * 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
WO2014198241A1 (en) * 2013-06-14 2014-12-18 Sunshine Lake Pharma Co., Ltd. Thio-1,2,4-triazole derivatives and method for preparing the same
CN103524440B (zh) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
JP6470761B2 (ja) * 2013-11-22 2019-02-13 クリスタル ファーマテック カンパニー、リミテッドＣｒｙｓｔａｌ Ｐｈａｒｍａｔｅｃｈ Ｃｏ．， Ｌｔｄ． レシヌラドおよびそのナトリウム塩の結晶形態
CN104557748A (zh) * 2014-01-25 2015-04-29 广东东阳光药业有限公司 硫代-1,2,4-三唑衍生物的新的固体形态
CN105315218A (zh) * 2014-07-17 2016-02-10 天津药物研究院 一种制备lesinurad中间体1-萘基三唑硫酮的方法
CN104341362B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104326998B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104326993B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341363B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104370842B (zh) * 2014-10-27 2016-07-13 张远强 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104341361B (zh) * 2014-10-27 2017-01-11 张远强 一种腈基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104370841B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104311498B (zh) * 2014-10-27 2016-04-06 张远强 烷氧基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104327000B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN104987311A (zh) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 一种[4-(4-环丙基萘-1-基)-5-硝基- 4h-[1,2,4]三唑-3-基硫烷基]-乙酸乙酯的制备方法及其中间体(5-硝基-4h-[1,2,4]三唑-3-基硫基)-乙酸乙酯
CN105017168A (zh) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
CN105153056A (zh) * 2015-07-01 2015-12-16 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
WO2017036884A1 (en) 2015-08-28 2017-03-09 Sandoz Ag A lesinurad, free form / lesinurad ethyl ester co-crystal
CN105566237B (zh) * 2016-03-01 2018-05-18 山东大学 一种治疗痛风的三唑巯乙酸类化合物的制备方法
EP3473617B1 (en) * 2016-06-17 2022-09-07 Medshine Discovery Inc. Halogenated compound and axially chiral isomers thereof
EP3281941B1 (en) 2016-08-11 2019-07-24 Zentiva K.S. Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid
EP3372592A1 (en) 2017-03-07 2018-09-12 Zentiva, k.s. Solid forms of lesinurad amine salts
US10351537B2 (en) * 2017-03-10 2019-07-16 Apotex Inc. Processes for the preparation of lesinurad and intermediates thereof
EP3315494A1 (en) 2017-04-19 2018-05-02 Química Sintética, S.A. Amorphous form of lesinurad and processes for its preparation
CN108947919B (zh) 2017-05-17 2023-05-02 上海奥博生物医药股份有限公司 一种抗痛风药Lesinurad的新型制备方法及其关键中间体
WO2019001325A1 (zh) * 2017-06-28 2019-01-03 苏州科睿思制药有限公司 雷西纳得的晶型xv及其制备方法
EP3498697A1 (en) 2017-12-12 2019-06-19 Química Sintética, S.A. Novel salts and polymorphs of lesinurad
DE112022002825T5 (de) 2021-05-28 2024-03-14 Sumitomo Chemical Company, Limited Verfahren zur Herstellung von Cycloalkylbromid

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US226186A (en) 1880-04-06 Car-coupling
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2009A (en) * 1841-03-18 Improvement in machines for boring war-rockets
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
JPS5641637B2 (zh) 1973-11-26 1981-09-29
US6832996B2 (en) * 1995-06-07 2004-12-21 Arthrocare Corporation Electrosurgical systems and methods for treating tissue
JPH07215940A (ja) 1994-01-27 1995-08-15 Torii Yakuhin Kk 抗ウイルス活性を有する化合物
JP2000510164A (ja) 1997-02-14 2000-08-08 バイエル・コーポレーシヨン 選択的神経ペプチドｙ受容体アンタゴニストとしてのアミド誘導体
US6245817B1 (en) * 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
JPH10243033A (ja) * 1997-02-28 1998-09-11 Oki Electric Ind Co Ltd 復調装置
ES2361146T3 (es) * 1998-03-27 2011-06-14 Janssen Pharmaceutica Nv Derivados de la piramidina inhibitatoria de vih.
PT1129096E (pt) 1998-11-12 2003-09-30 Neurocrine Biosciences Inc Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos
WO2000037471A1 (en) * 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: gaba brain receptor ligands
CN1178913C (zh) * 1998-12-25 2004-12-08 盐野义制药株式会社 具有hiv整合酶抑制活性的芳族杂环化合物
US6593077B2 (en) * 1999-03-22 2003-07-15 Special Materials Research And Technology, Inc. Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate
PL364658A1 (en) 2001-03-02 2004-12-13 Smithkline Beecham Corporation Benzophenones as inhibitors of reverse transcriptase
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
JP2005529923A (ja) 2002-05-13 2005-10-06 イーライ・リリー・アンド・カンパニー 肥満および糖尿病の治療におけるメラニン凝集ホルモンアンタゴニストとして使用するための多環式化合物
EA009478B1 (ru) * 2002-08-23 2008-02-28 Ардеа Байосайенсиз, Инк. Ненуклеозидные ингибиторы обратной транскриптазы
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
PL227577B1 (pl) 2003-02-07 2017-12-29 Janssen Pharmaceutica Nv Zastosowanie pochodnych pirymidyny do wytwarzania leku do zapobiegania zakażeniu wirusem HIV oraz kompozycja farmaceutyczna
DE602004031641D1 (de) 2003-09-25 2011-04-14 Janssen Pharmaceutica Nv Die replikation von hiv hemmende purinderivate
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
US7517998B2 (en) 2004-06-01 2009-04-14 Boehringer Ingelheim International Gmbh Non nucleoside reverse transcriptase inhibitors
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
EP2135608B8 (en) * 2004-08-25 2012-03-21 Ardea Biosciences, Inc. S-triazolyl alpha -mercaptoacetanilides as inhibitors of HIV reverse transcriptase
SI2217577T1 (sl) * 2007-11-27 2014-11-28 Ardea Biosciences, Inc. Nove spojine in sestavki ter metode uporabe
EP2349258A1 (en) 2008-10-24 2011-08-03 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( l-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triazol-3-ylthio) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
WO2010048592A1 (en) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
TWM377707U (en) * 2009-09-16 2010-04-01 Nat Energy Technology Co Ltd Assembly of power supply

Also Published As

Publication number Publication date
EP2402011A1 (en) 2012-01-04
US20110190491A1 (en) 2011-08-04
PL2135608T3 (pl) 2012-07-31
US8481581B2 (en) 2013-07-09
US8946273B2 (en) 2015-02-03
CY2016028I1 (el) 2016-12-14
AU2005280130C9 (en) 2010-03-04
SG155246A1 (en) 2009-09-30
BRPI0514630B1 (pt) 2020-09-15
MX2007002236A (es) 2007-07-09
AU2009217458A1 (en) 2009-10-15
HUS1600034I1 (hu) 2016-09-28
US20120283301A1 (en) 2012-11-08
DK2135608T3 (da) 2012-01-23
WO2006026356A3 (en) 2006-08-10
PT2135608E (pt) 2012-01-13
US20100267724A2 (en) 2010-10-21
WO2006026356A2 (en) 2006-03-09
HRP20130075T1 (hr) 2013-02-28
AU2009217458B2 (en) 2009-11-19
CN101083987A (zh) 2007-12-05
LU93169I2 (fr) 2016-10-10
IL181523A (en) 2013-12-31
CA2578068C (en) 2011-08-09
ECSP077322A (es) 2007-04-26
ES2374773T3 (es) 2012-02-21
JP2012077088A (ja) 2012-04-19
IN2014CN03762A (zh) 2015-09-25
SI2135608T1 (sl) 2012-03-30
US7947721B2 (en) 2011-05-24
NZ553534A (en) 2010-10-29
IL201546A (en) 2013-10-31
CY1112221T1 (el) 2015-12-09
RS52632B (en) 2013-06-28
NL300825I2 (zh) 2017-01-24
FR16C0031I2 (fr) 2017-03-31
US20110313157A1 (en) 2011-12-22
BRPI0514630B8 (pt) 2021-05-25
JP4952943B2 (ja) 2012-06-13
US8252828B2 (en) 2012-08-28
AU2005280130C1 (en) 2010-02-18
KR101241716B1 (ko) 2013-03-08
NZ581376A (en) 2011-05-27
EP1789039A4 (en) 2009-08-05
CY2016028I2 (el) 2016-12-14
EP2433633A1 (en) 2012-03-28
ATE540677T1 (de) 2012-01-15
BRPI0520870B8 (pt) 2021-05-25
IL219131A0 (en) 2012-06-28
US20150094284A1 (en) 2015-04-02
JP2008510828A (ja) 2008-04-10
EP2135608A1 (en) 2009-12-23
US20100069645A1 (en) 2010-03-18
KR20070054694A (ko) 2007-05-29
BRPI0514630A (pt) 2008-06-17
EP1789039A2 (en) 2007-05-30
AU2005280130B2 (en) 2009-09-10
JP5457472B2 (ja) 2014-04-02
BRPI0520870B1 (pt) 2020-11-10
US20100081827A1 (en) 2010-04-01
EA014737B1 (ru) 2011-02-28
US8003681B2 (en) 2011-08-23
CN101817793A (zh) 2010-09-01
HK1133582A1 (en) 2010-04-01
ATE528001T1 (de) 2011-10-15
EP2135608B8 (en) 2012-03-21
LTPA2016024I1 (lt) 2016-09-12
CN101083987B (zh) 2011-01-26
EP1789039B1 (en) 2012-01-11
US20180002296A1 (en) 2018-01-04
EP2609917A1 (en) 2013-07-03
CA2578068A1 (en) 2006-03-09
AU2005280130A1 (en) 2006-03-09
EA200700488A1 (ru) 2007-08-31
EA015846B1 (ru) 2011-12-30
AU2009217458A8 (en) 2009-10-29
EP2402011B1 (en) 2012-11-14
EA200901186A1 (ru) 2010-04-30
CN101817793B (zh) 2014-01-08
ME01512B (me) 2014-04-20
LTC2135608I2 (lt) 2017-07-25
ES2380604T3 (es) 2012-05-16
EP2135608B1 (en) 2011-10-12
SG185992A1 (en) 2012-12-28
IL181523A0 (en) 2007-07-04
US20080176850A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
FR16C0031I1 (zh)
GB2371066B8 (en) Tubulars with expandable cells and locking mechanisms
WO2005032488A3 (en) 2,4-dioxo-3-quinazolinylaryl sulfonylureas
WO2003037864A1 (fr) Compose indolique, et utilisation a des fins therapeutiques
DE602005011031D1 (en) Phosphoindole als hiv-inhibitoren
AU2003243765A8 (en) 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors
USD522907S1 (en) Gemstone (I)
USD483954S1 (en) Fabric
UA89200C2 (ru) S-ТРИАЗОЛИЛ-б-МЕРКАПТОАЦЕТАНИЛИДЫ КАК ИНГИБИТОРЫ ОБРАТНОЙ ТРАНСКРИПТАЗЫ ВИЧ
DK1399142T3 (da) Anvendelse af acetyl-L-carnitin i kombination med biotin til behandlingen af patienter med type-2 insulinresistent diabetes mellitus
USD521586S1 (en) Billiard table
USD475098S1 (en) Craft kit construction component—leg form
WO2004096147A3 (en) Oxo-pyrimidine compounds
USD472406S1 (en) Table
AR028458A1 (es) Un estuche de combinacion usado en el tratamiento del paludismo
RU2006146820A (ru) Средство связи
TH54449EX (th) อุปกรณ์ควบคุมไร้สาย
JP2003334596A5 (zh)
AP2005003429A0 (en) 5,7-Diaminopyrazolo Ä4,3-DÜ pyrimidines useful in the treatment of hypertension.